Course Director

Peter Lio, MD
Peter Lio, MD

Northwestern University
Feinberg School of Medicine
Chicago Integrative Eczema Center
Chicago, Illinois, USA

Accredited by

Oakstone Publishing

View Activity Materials

Activity Details

Credit Types:CME
Credit Amount:0.5 Credits
Release Date:2020-Oct-30
Expiration Date:2021-Oct-29
Estimated Time for Completion:30 minutes
Registration Required:No
Cost:Free of Charge


This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Activity Description and Educational Objectives

In this activity, an expert in pediatric dermatology discusses recent data from the Revolutionizing Atopic Dermatitis virtual conference.

  • Describe the impact of moderate-to-severe atopic dermatitis (AD) on pediatric and adolescent patients’ quality of life
  • Evaluate the latest clinical evidence for available and emerging biologic therapies for pediatric and adolescent patients with moderate-to-severe AD
  • Outline strategies to apply the latest evidence for biologic therapies to practice, now and into the future

Target Audience

This activity has been designed to meet the educational needs of pediatricians, dermatologists, and other clinicians involved in the treatment of moderate-to-severe AD in children and adolescents.

Faculty Disclosure Statement / Conflict of Interest Policy

Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, medical reviewers, and editorial staff disclose no relevant financial relationships with commercial interests.

Course Director and Faculty

Peter Lio, MD
Clinical Assistant Professor of Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Founding Director
Chicago Integrative Eczema Center
Chicago, Illinois, USA

Peter Lio, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AbbVie; Amyris, Inc.; Burt's Bees; Dermira; Eli Lilly and Company; Exeltis; Franklin BioScience; Kiniksa Pharmaceuticals, Ltd.; LEO Laboratories Ltd; L'Oreal USA Inc.; Odeza LLC; Theraplex; TopMD; and Unilever.
Grant/Research Support from AbbVie; AOBiome, LLC; La Fondation pour la Dermatite Atopique; National Eczema Association; and Regeneron.
Speakers Bureau participant with Galderma USA; La Roche-Posay Laboratorie Pharmaceutique; Pfizer Inc.; Pierre Fabre Dermatologie; and Regeneron.
Stock Shareholder in LearnHealth/LearnSkin; Medable; and Modernizing Medicine.
Advisory Board for Altus Labs; Arbonne; Bodewell; DermaTap, Inc.; Dermavant Sciences; DermVeda; gpower, inc.; IntraDerm Pharmaceuticals; Johnson & Johnson Consumer Products Company; Menlo Therapeutics; Micreos Human Health B. V.; Modernizing Medicine; National Eczema Association; Realm Therapeutics; Regeneron; Sanofi US Services; Syncere Skin Systems; UCB; Verrica Pharmaceuticals Inc; and YobeeCare Inc.
Other Financial or Material Support from Theraplex.

Answers in CME Medical Director

Sonia Schursky, MD, has no financial interests/relationships or affiliations in relation to this activity.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use in certain jurisdictions. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our materials. No responsibility is taken for errors or omissions in our materials.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing and Answers in CME. Oakstone Publishing is accredited by the ACCME to provide continuing medical education for physicians.

Oakstone Publishing designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (

This CME activity is jointly provided by Oakstone Publishing and Answers in CME.

Requirements for Successful Completion

To receive credit, participants must complete the activity, the post-test, and the evaluation form prior to the expiration date noted below. There are no pre-requisites and there is no fee to participate in this activity or to receive credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form. Consult your professional licensing board for information about your eligibility to claim credit for participation in this educational activity. A minimum performance level of 80% is needed.

Media: Enduring Material
Release and Expiration Dates: October 30, 2020 - October 29, 2021
Time to Complete: 30 minutes


The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Answers in CME or any of its supporters.

© 2018-2020, Answers in CME

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.